MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation

Breast cancer is a heterogeneous disease comprising a diversity of tumor subtypes that manifest themselves in a wide variety of clinical, pathological, and molecular features. One important subset, luminal breast cancers, comprises two clinically distinct subtypes luminal A and B each of them endowe...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2017-05, Vol.30 (5), p.682-697
Main Authors: Yousef, Einas M, Furrer, Daniela, Laperriere, David L, Tahir, Muhammad R, Mader, Sylvie, Diorio, Caroline, Gaboury, Louis A
Format: Article
Language:English
Subjects:
692/308/53
692/308/53/2423
Biomarkers, Tumor - analysis
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cell Proliferation
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Ki-67 Antigen - analysis
Ki-67 Antigen - biosynthesis
Laboratory Medicine
Medicine
Medicine & Public Health
Minichromosome Maintenance Complex Component 2 - analysis
Minichromosome Maintenance Complex Component 2 - biosynthesis
Neoplasm Grading - methods
original-article
Pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is a heterogeneous disease comprising a diversity of tumor subtypes that manifest themselves in a wide variety of clinical, pathological, and molecular features. One important subset, luminal breast cancers, comprises two clinically distinct subtypes luminal A and B each of them endowed with its own genetic program of differentiation and proliferation. Luminal breast cancers were operationally defined as follows: Luminal A: ER+, PR+, HER2-, Ki-67
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2016.231